Recent News

• 03.18.2026 - CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
• 03.16.2026 - CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
• 03.16.2026 - CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
• 03.16.2026 - CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
• 03.04.2026 - CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
• 02.24.2026 - Varsetatug masetecan (CX-2051): Unlocking EpCAM as a Cancer Target via a Masked EPCAM-Directed Topo1 ADC
• 02.04.2026 - CytomX Therapeutics to Present at Upcoming February Conferences

Recent Filings

• 03.16.2026 - EX-99.1 EX-99.1
• 03.16.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.16.2026 - 8-K Current report
• 03.16.2026 - S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
• 03.16.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.04.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.05.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities